Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diuretic and Cool Dialysate in Hemodialysis
NCT02593526Terminated
- Sponsor
- The University of New Mexico
- Start
- Jan 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of bumetanide in chronic kidney disease (CKD) (4 arms), sponsored by The University of New Mexico. Primary endpoint: Slow the Rate of Residual Renal Function at 6 months. Started Jan 2017; status: terminated.
02
Drugs
bumetanide
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02593526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593526.